Our finding raises the intriguing possibility that activation of the Akt-β-catenin pathway might be a common mechanism for conferring resistance to cancer treatment, not only to EGF-TKIs, but also to other types of treatment, including chemotherapy and radiotherapy. The gene discussed is AKT1; the disease is cancer.